01/09/2026
🔬 What Is Retatrutide—and Why Is Everyone Talking About It?
A new investigational medication called retatrutide is generating a lot of interest in the medical weight-loss space—and for good reason.
Retatrutide is a triple-hormone receptor agonist, targeting GLP-1, GIP, and glucagon, which play key roles in appetite regulation and metabolism. In a Phase 2 clinical trial published in The New England Journal of Medicine, participants achieved up to 24.2% average weight loss at 48 weeks—an impressive result when compared to outcomes seen in separate trials of semaglutide or tirzepatide.
That said, it’s important to understand the full context. Because no head-to-head studies currently exist, retatrutide cannot yet be considered definitively more effective—and it remains investigational at this time.
👨‍⚕️ Dr. Joshua Silva breaks this down clearly in our latest blog, explaining:
• How retatrutide works
• What the research actually shows
• How it compares (and doesn’t compare) to current GLP-1 and GLP-1/GIP therapies
• What patients should know right now
đź“– Read the full, evidence-based breakdown on our website:
👉 https://www.poterehealthmd.com/post/retatrutide-vs-semaglutide-tirzepatide-weight-loss
At Potere Health MD, we believe in informed decisions, medical integrity, and staying ahead of the science—without the hype.
Retatrutide is a next-generation weight-loss medication under study. See how it compares to semaglutide and tirzepatide, what trials show so far, and what patients should know today.